Drug Profile
Research programme: RNAi therapeutics - Alnylam/University of California San Francisco
Alternative Names: GNAQ - AlnylamLatest Information Update: 05 May 2011
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; University of California at San Francisco
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 05 May 2011 No development reported - Preclinical for Malignant melanoma in USA (Parenteral)
- 15 Dec 2008 Preclinical trials in Malignant melanoma in USA (Parenteral)